Hanall Biopharma Co., Ltd. (KRX:009420)
25,100
+200 (0.80%)
At close: Jun 5, 2025, 3:30 PM KST
Hanall Biopharma Revenue
Hanall Biopharma had revenue of 36.15B KRW in the quarter ending March 31, 2025, with 6.03% growth. This brings the company's revenue in the last twelve months to 141.00B, up 0.57% year-over-year. In the year 2024, Hanall Biopharma had annual revenue of 138.94B with 2.99% growth.
Revenue (ttm)
141.00B
Revenue Growth
+0.57%
P/S Ratio
9.03
Revenue / Employee
463.82M
Employees
304
Market Cap
1,273.57B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 138.94B | 4.03B | 2.99% |
Dec 31, 2023 | 134.91B | 24.91B | 22.65% |
Dec 31, 2022 | 110.00B | 8.40B | 8.27% |
Dec 31, 2021 | 101.59B | 12.99B | 14.66% |
Dec 31, 2020 | 88.60B | -19.85B | -18.30% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,898.69B |
Celltrion | 3,662.23B |
ALTEOGEN | 151.65B |
Yuhan | 2,114.76B |
SK Biopharmaceuticals | 578.00B |
HLB Co., Ltd. | 74.64B |
PharmaResearch | 392.31B |
LigaChem Biosciences | 146.42B |